Is Lexaria Bioscience struggling financially?

Yes, by its own account. Lexaria Bioscience told the SEC on 13 Jul 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed Jul 2026

15/100

Critical

Sector: Biotech/Pharma
Market cap: $18.0M
Source filing: 10-Q 13 Jul 2026
Balance sheet: 31 May 2026

Cash runway

3months

If the burn speeds up

Empty by Aug 2026
5months

If it eases off

Empty by Oct 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$3.6M

Cash burned over the last 12 months

$11.6M

What Lexaria Bioscience told the SEC

…any, and the receipt of payments under any current or future collaborations into which we may enter. The recurring losses and negative net cash flows raise substantial doubt as to the Company’s ability to continue as a going concern. During the nine months ended May 31, 2026, we raised $ 6.5 million in net proceeds from the sale of securities pursuant to our Registered Direct Offerings which closed in September…

LEXARIA BIOSCIENCE CORP., Form 10-Q, filed 13 Jul 2026.

Read the filing on SEC.gov

What this means

Not a bankruptcy filing, and not a prediction.
It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

34.7% share-count increase The company issued stock. Each share now owns 25.8% less of the business than a year ago, before any change in the price.
Cash burn is narrowing It is spending 31% less cash per year than it was, so the runway above is lengthening rather than shortening.

Cash runway

The runway math

What Lexaria Bioscience told the SEC

What this means

What else the numbers show

Other Biotech/Pharma companies that filed the doubt